However, with the identification of patients with homozygous or compound heterozygous SACS mutations worldwide, it is now evident that the clinical features can vary widely, some of them lacking spasticity or peripheral neuropathy, and nonmotor symptoms such as cognitive decline, ID, and behavioral abnormalities can be prominent and even dominant clinical features [51]. This evidence concerns the gene SACS and peripheral neuropathy.